Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

[ad_1] Protara Therapeutics Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24 Company initiated ADVANCED-2 trial evaluating TARA-002 in NMIBC…